Avulux lands FDA de novo classification for light-sensitive migraine lenses

Avulux received FDA de novo classification for its light-filtering lens technology designed for light-sensitive migraine sufferers. The lenses block up to 97% of blue, amber, and red light wavelengths while transmitting green light. De novo classification establishes a new regulatory pathway for the device type.